AC
BLTE

Armistice Capital’s Belite Bio BLTE Stock Holding History

Armistice Capital’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-167,930
Closed -$10.6M – 235
2024
Q4 		$10.6M Buy
+167,930
New +$11.1M 0.14% 89
2024
Q3 		– Sell
-148,000
Closed -$6.76M – 263
2024
Q2 		$6.76M Buy
+148,000
New +$6.41M 0.09% 102
2024
Q1 		– Sell
-36,000
Closed -$1.65M – 348
2023
Q4 		$1.65M Buy
+36,000
New +$1.38M 0.02% 160
2023
Q3 		– Sell
-210,915
Closed -$3.01M – 256
2023
Q2 		$3.01M Buy
+210,915
New +$4.79M 0.04% 131

Other funds holding BLTE

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $429M AUM 52.52% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Armistice Capital's BLTE Position: Q1 2025 in Review

Armistice Capital sold out of Belite Bio (BLTE) in Q1 2025, closing a stake of 167,930 shares — an estimated $10.6M sold.

Armistice Capital first reported a position in BLTE in Q2 2023 and held it in 4 quarters. The position peaked at $10.6M in Q4 2024. 18 funds tracked by Wall St. Rank hold BLTE as of Q1 2025.

  • Armistice Capital reported no remaining Belite Bio position as of Q1 2025 after selling out during the quarter.
  • Armistice Capital sold 167,930 Belite Bio shares in Q1 2025, an estimated $10.6M.
  • Armistice Capital first reported a position in Belite Bio in Q2 2023 and held it in 4 quarters.
  • Armistice Capital's Belite Bio position peaked at $10.6M in Q4 2024.
  • 18 funds tracked by Wall St. Rank held Belite Bio as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.